Now imagine that loss extending to days or even months. That’s the kind of world we could face if an EMP, or Electromagnetic ...
Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G protein ...
This marks a significant advancement from earlier EMP technology, with CHAMP’s design focusing on precision and targeted ...
Orion is dedicated to improving the lives of the patients through innovative R&D and gaining access to Abilita's proprietary EMPâ„¢ technology provides us new opportunities on our path to develop ...
Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the discovery, development and ...
Under the terms of the agreement, Orion gains access to Abilita's proprietary Enabled Membrane Protein (EMP) technology for the discovery of novel antibody therapeutics to challenging GPCR (G protein ...